"We at RMIA are so happy to have contributed to Sara and Michael's dream of becoming parents," said Jacques Stassart, MD, director of IVF services. "IVF can be a long and challenging process for some couples, however, the end result is always worth all of the hard work. In Sara and Michael's case, it's a beautiful baby girl and a substantial start to her college education. We are proud to be a part of Sara's 'little miracle.'"
Runner-up Amy Crider of Jacksonville, FL, will receive $2,500 for an education fund for her five-month-old daughter, Reece. Ten honorable mention winners from around the country will each receive a $500 education fund.
About MENOPUR and BRAVELLE
MENOPUR and BRAVELLE are not indicated in women with ovarian failure, uncontrolled thyroid and adrenal dysfunction, pituitary or hormone dependent tumor, abnormal uterine bleeding of undetermined origin, or ovarian cysts or enlargement not due to polycystic ovary syndrome. Like all gonadotropins, these are potent substances capable of causing mild to severe adverse reactions, including Ovarian Hyper Stimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with MENOPUR and/or BRAVELLE may result in multiple births.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned,
international pharmaceutical company, manufactures and markets the largest
family of fertility treatments in the U.S. The Company markets MENOPUR,
BRAVELLE, REPRONEX(R) (menotropins for injection, USP), NOVAREL(R)
(chorionic gonadotropin for injection, USP) and ENDOMETRIN(R)
|SOURCE Ferring Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved